Clinical Trial Update: Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-escalation trial of a contrast agent to delineate urological anatomy during minimally invasive surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intraoperative Ureter Injury

Drugs mentioned

• Contrast Agent

Snippet

Sponsor: Li-Cor, Inc. | Conditions: Intraoperative Ureter Injury | Phase 1, Phase 2 | Status: COMPLETED